Infliximab and Infliximab-abda to be used in this study are TNFα inhibitors currently FDA-approved for the treatment of autoimmune disorders, including Crohn’s disease and rheumatoid arthritis (ClinicalTrials.gov Identifier: NCT04425538). This evidence concerns the gene TNF and rheumatoid arthritis.